Category News

Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines

As part of Sanofi’s commitment to developing a diverse portfolio of best-in-class vaccines, the company has entered into a co-exclusive licensing agreement with Novavax, a biotechnology company headquartered in Maryland, US. The terms of the agreement include: a co-exclusive license to co-commercialize Novavax’s current stand-alone adjuvanted…

Dyno Therapeutics and NVIDIA collaborate on AI to accelerate the design of high-performance biological sequences

Dyno Therapeutics announced a collaboration with NVIDIA to leverage Dyno’s field-leading artificial intelligence (AI) and in vivo experimentation capabilities, along with the built-to-scale NVIDIA BioNeMo AI-powered drug design platform, to help advance biological sequence design. Everything life does is controlled by biological sequences: DNA, RNA, and proteins. The…

Results from the efficacy portion of the Phase 3 SOLARIS trial

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, and Medincell, today announced results from the efficacy portion of the Phase 3 Subcutaneous OLAnzapine extended-Release Injection Study (SOLARIS) trial evaluating TEV-‘749 in adult patients with schizophrenia compared to placebo.  Results demonstrated that TEV-‘749…